Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
25/08/2026 12:38
BRIEF-Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan Aug 25 (Reuters) - BioCryst Pharmaceuticals, Inc. BCRX.O:
BIOCRYST ANNOUNCES APPROVAL OF ORLADEYO® FOR PEDIATRIC HAE PATIENTS IN JAPAN
Source text: ID:nGNX3pXvpc
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026